A team led by Thomas B. Nutman, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has completed a large-scale analysis of most of the proteins produced by Brugia malayi , one kind of parasitic worm that causes lymphatic filariasis, or elephantiasis. The greatly swollen lower limbs that can result from chronic infection with this mosquito-borne parasite can be severely disabling.
The investigators characterized 7,103 proteins produced in various stages of the worm's lifecycle, including male and female adult forms that live in the body's lymphatic system; asexual stages that circulate in human blood; and the larval stage that first infects humans.
The nature and relative amounts of proteins produced during successive stages of the worm's lifecycle provide clues to their likely importance in creating and maintaining infection. For example, proteins made in abundance by larval worms might serve as targets for developing vaccines to prevent infections. Proteins made in large amounts by adult worms might serve as targets for developing drugs to treat infections and potentially halt transmission of the parasite from an infected person to a potential mosquito carrier.
In addition to identifying the worm-made proteins, the team also characterized most of the proteins made by Wolbachia , bacteria that live inside B. malayi . Human inflammatory immune responses to the combined presence of Wolbachia and B. malayi are thought to be responsible for many symptoms of lymphatic filariasis.
Sequencing of the B. malayi genome, which enabled this research on the worm's proteins to be carried out, was completed by National Institutes of Health-funded researchers in 2007.
ARTICLE: S Bennuru et al. Stage-specific proteomic expression patterns of the human filarial parasite Brugia malayi and its endosymbiont Wolbachia . Proceedings of the National Academy of Sciences USA Early Edition DOI: 10.1073/pnas.1011481108 (2011).
WHO: Thomas B. Nutman, M.D., deputy chief, Laboratory of Parasitic Diseases, NIAID, is available to discuss this paper.
CONTACT: To schedule interviews, please contact Anne A. Oplinger, 301-402-1663, aoplinger@niaid.nih.gov .
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov/ .
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/ .
Proceedings of the National Academy of Sciences